InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
InspireMD (NSPR) has appointed Scott R. Ward to its Board of Directors. Ward, who most recently served as CEO and President of Cardiovascular Systems until its acquisition by Abbott in April 2023, brings over 40 years of healthcare industry experience, including 30 years at Medtronic in senior leadership roles. The appointment comes as InspireMD approaches potential U.S. approval of its CGuard Prime carotid stent system. Ward's extensive operational experience in the cardiovascular space is expected to contribute to the company's strategy in advancing its carotid platform and pipeline innovations, including CAS, TCAR, and Neuro focus.
InspireMD (NSPR) ha nominato Scott R. Ward nel suo Consiglio di Amministrazione. Ward, che ha ricoperto l'ultimo ruolo di CEO e Presidente di Cardiovascular Systems fino alla sua acquisizione da parte di Abbott nell'aprile 2023, porta con sé oltre 40 anni di esperienza nel settore sanitario, di cui 30 anni trascorsi in Medtronic in posizioni di leadership senior. La nomina arriva mentre InspireMD si avvicina a una potenziale approvazione negli Stati Uniti del suo sistema di stent carotideo CGuard Prime. L'ampia esperienza operativa di Ward nel settore cardiovascolare è prevista per contribuire alla strategia dell'azienda nell'avanzare la sua piattaforma carotidea e le innovazioni della pipeline, tra cui CAS, TCAR e un focus su Neuroscienze.
InspireMD (NSPR) ha nombrado a Scott R. Ward en su Junta Directiva. Ward, quien más recientemente se desempeñó como CEO y Presidente de Cardiovascular Systems hasta su adquisición por Abbott en abril de 2023, aporta más de 40 años de experiencia en la industria de la salud, incluidos 30 años en Medtronic en roles de liderazgo senior. La designación se produce mientras InspireMD se acerca a una posible aprobación en EE. UU. de su sistema de stent carotídeo CGuard Prime. Se espera que la extensa experiencia operativa de Ward en el espacio cardiovascular contribuya a la estrategia de la empresa para avanzar en su plataforma carotídea y las innovaciones de la línea de productos, incluyendo CAS, TCAR y un enfoque en neurociencia.
InspireMD (NSPR)는 스콧 R. 워드를 이사회에 임명했습니다. 워드는 2023년 4월 Abbott에 인수되기 전까지 Cardiovascular Systems의 CEO 및 사장으로 최근까지 근무했으며, 40년 이상의 의료 산업 경험을 보유하고 있습니다. 이 중 30년은 Medtronic에서 고위 리더십 직책으로 일했습니다. 이번 임명은 InspireMD가 자사의 CGuard Prime 경동맥 스텐트 시스템의 미국 잠재적 승인을 목전에 두고 이루어졌습니다. 심혈관 분야에서의 워드의 광범위한 운영 경험은 회사의 경동맥 플랫폼 및 파이프라인 혁신을 발전시키는 전략에 기여할 것으로 기대됩니다. 여기에는 CAS, TCAR, 그리고 신경학적 초점이 포함됩니다.
InspireMD (NSPR) a nommé Scott R. Ward au sein de son Conseil d'Administration. Ward, qui a récemment exercé les fonctions de PDG et de Président de Cardiovascular Systems jusqu'à son acquisition par Abbott en avril 2023, apporte plus de 40 ans d'expérience dans l'industrie de la santé, dont 30 ans chez Medtronic dans des postes de direction. Cette nomination intervient alors qu'InspireMD se rapproche d'une éventuelle approbation aux États-Unis de son système de stents carotidiens CGuard Prime. L'expérience opérationnelle étendue de Ward dans le domaine cardiovasculaire devrait contribuer à la stratégie de l'entreprise pour faire avancer sa plateforme carotidienne et les innovations de son pipeline, y compris CAS, TCAR et un focus sur les Neurosciences.
InspireMD (NSPR) hat Scott R. Ward in seinen Vorstand berufen. Ward, der zuletzt als CEO und Präsident von Cardiovascular Systems tätig war, bis das Unternehmen im April 2023 von Abbott übernommen wurde, bringt über 40 Jahre Erfahrung in der Gesundheitsbranche mit, darunter 30 Jahre in leitenden Positionen bei Medtronic. Die Ernennung erfolgt, während InspireMD der möglichen Genehmigung seines CGuard Prime Karotisstentsystems in den USA näher kommt. Wards umfassende operative Erfahrung im kardiovaskulären Bereich wird voraussichtlich zur Strategie des Unternehmens beitragen, die Karotis-Plattform und die Innovationen in der Pipeline, einschließlich CAS, TCAR und Neuro-Fokus, weiter voranzutreiben.
- Strategic appointment of experienced medical technology executive with 40+ years in healthcare
- Company approaching potential U.S. approval for CGuard Prime product
- Addition of former Medtronic senior executive strengthens Board expertise in cardiovascular space
- None.
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023.
Paul Stuka, Chairman of the Board of InspireMD, stated, “We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his insights will be invaluable as the Company rapidly approaches potential U.S. approval of CGuard Prime, the most significant value inflection point in its history. I look forward to Scott’s contributions and believe he will have an immediate impact.”
Marvin Slosman, Chief Executive Officer of InspireMD and Board member, commented, “The addition of Scott to our Board adds tremendous experience in the cardiovascular field, with a track record of growth and innovation as an executive, a board member and investor. His experience and legacy in the space will help guide us through our next stages of advancing our novel carotid platform as part of a comprehensive approach to catalyzing on the market shift toward a stent first standard while also guiding our pipeline of innovation, including our CAS, TCAR and Neuro focus.”
“I am very excited to join the InspireMD Board at such a transformational time for the company,” added Mr. Ward. “With an impressive body of data demonstrating the superior short- and long-term patient outcomes of its novel CGuard Prime carotid stent system, I believe that CGuard, when approved in the U.S., will quickly become a new standard-of-care for carotid intervention and stroke prevention. I look forward to working with my fellow Board members and the InspireMD leadership team to achieve this goal.”
Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s or directors’ expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch.. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently; actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
FAQ
Who is the new board member appointed to InspireMD (NSPR)?
What is InspireMD's (NSPR) main product pending approval in the US?
What is Scott Ward's previous experience before joining InspireMD (NSPR)?
